Polymeric Oncolytic Adenovirus for Cancer Gene Therapy

Overview

Journal J Control Release

Specialty Pharmacology

Date 2015 Oct 11

PMID 26453806

Citations 30

Authors

Joung-Woo Choi

Young Sook Lee

Chae-Ok Yun

Sung Wan Kim

Affiliations

Soon will be listed here.

Abstract

Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research.

Citing Articles

Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8 T cell infiltration.

Wang S, Kong L, Wang L, Zhuang Y, Guo C, Zhang Y J Exp Clin Cancer Res. 2025; 44(1):97.

PMID: 40082916 PMC: 11907943. DOI: 10.1186/s13046-025-03358-y.

Recombinant VSVs: A Promising Tool for Virotherapy.

Vorona K, Moroz V, Gasanov N, Karabelsky A Acta Naturae. 2025; 16(4):4-14.

PMID: 39877014 PMC: 11771844. DOI: 10.32607/actanaturae.27501.

An Engineered Self-biomineralized Oncolytic Adenovirus Induces Effective Antitumor Immunity and Synergizes With Immune Checkpoint Blockade.

Wang S, Yang X, Ma Y, Wu J, Jin K, Zhao R Cancer Immunol Res. 2024; 12(11):1640-1654.

PMID: 39093821 PMC: 11532738. DOI: 10.1158/2326-6066.CIR-23-0957.

Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer.

Wang Z, Sun P, Li Z, Xiao S Cancers (Basel). 2023; 15(21).

PMID: 37958464 PMC: 10650136. DOI: 10.3390/cancers15215291.

Recent advances in oncolytic virus therapy for hepatocellular carcinoma.

Zhu L, Lei Y, Huang J, An Y, Ren Y, Chen L Front Oncol. 2023; 13:1172292.

PMID: 37182136 PMC: 10169724. DOI: 10.3389/fonc.2023.1172292.

References

DeWeese T, Van der Poel H, Li S, Mikhak B, Drew R, Goemann M . A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001; 61(20):7464-72. View

Ferguson M, Lemoine N, Wang Y . Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012; 2012:805629. PMC: 3287020. DOI: 10.1155/2012/805629. View

Cawood R, Hills T, Wong S, Alamoudi A, Beadle S, Fisher K . Recombinant viral vaccines for cancer. Trends Mol Med. 2012; 18(9):564-74. DOI: 10.1016/j.molmed.2012.07.007. View

Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G . Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 2007; 99(23):1768-81. DOI: 10.1093/jnci/djm229. View

Kim J, Li Y, Kim S, Lee D, Yun C . Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex. Biomaterials. 2013; 34(19):4622-31. DOI: 10.1016/j.biomaterials.2013.03.004. View

Gajria D, Chandarlapaty S . HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011; 11(2):263-75. PMC: 3092522. DOI: 10.1586/era.10.226. View

Freytag S, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D . Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2014; 89(2):268-76. PMC: 4026796. DOI: 10.1016/j.ijrobp.2014.02.034. View

Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E . Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001; 19(2):289-98. DOI: 10.1200/JCO.2001.19.2.289. View

Kim E, Kim J, Shin H, Lee H, Yang J, Kim J . Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther. 2003; 14(15):1415-28. DOI: 10.1089/104303403769211637. View

10.

Tannock I, Rotin D . Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989; 49(16):4373-84. View

11.

Park Y, Kang E, Kwon O, Hwang T, Park H, Lee J . Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J Control Release. 2010; 148(1):75-82. DOI: 10.1016/j.jconrel.2010.06.027. View

12.

Garcia-Castro J, Alemany R, Cascallo M, Martinez-Quintanilla J, Arriero M, Lassaletta A . Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 2010; 17(7):476-83. DOI: 10.1038/cgt.2010.4. View

13.

Hinata N, Shirakawa T, Terao S, Goda K, Tanaka K, Yamada Y . Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University. Int J Urol. 2006; 13(6):834-7. DOI: 10.1111/j.1442-2042.2006.01418.x. View

14.

Lee Y, Kim J, Choi K, Choi I, Kim H, Cho S . Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res. 2006; 12(19):5859-68. DOI: 10.1158/1078-0432.CCR-06-0935. View

15.

Kim J, Lee Y, Kim H, Huang J, Yoon A, Yun C . Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst. 2006; 98(20):1482-93. DOI: 10.1093/jnci/djj397. View

16.

Brenner M, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J . Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000; 11(10):1477-88. DOI: 10.1089/10430340050057549. View

17.

Zhang Y, Chirmule N, Gao G, Qian R, Croyle M, Joshi B . Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001; 3(5 Pt 1):697-707. DOI: 10.1006/mthe.2001.0329. View

18.

Ilett E, Prestwich R, Kottke T, Errington F, Thompson J, Harrington K . Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009; 16(5):689-99. PMC: 4562026. DOI: 10.1038/gt.2009.29. View

19.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I . Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology. 2014; 3:e28694. PMC: 4091053. DOI: 10.4161/onci.28694. View

20.

Jain R . Barriers to drug delivery in solid tumors. Sci Am. 1994; 271(1):58-65. DOI: 10.1038/scientificamerican0794-58. View